Program
Methadone
Also written as “methadone” and “fosamprenavir + ritonavir + methadone”.
Its studies are mostly in Infections · Hepatitis C · Pain · Opioid-Related Disorders · Hepatitis C, Chronic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Indivior Pharmaceuticals | 10 open or running | phase 4since Jan 17, 2006 | Jan 17, 2006 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Jul 2, 2009 | Jul 2, 2009 | none ahead |
| Lyndra | 10 open or running | phase 1since Jan 20, 2022 | Jan 20, 2022 | none ahead |
| RECORDATI GROUP | 10 open or running | phase 3since Feb 14, 2013 | Feb 14, 2013 | none ahead |
Also a collaborator on its studies: Vertex Pharmaceuticals, aesca-pharma-gmbh, basilea-pharmaceutica-international-ltd and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 17, 2006First study: phase 4 study in Hepatitis C, ChronicNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT00279565 · 128 enrolled
- Jul 2, 2009Johnson & Johnson's first study: phase 1 study in Healthy ParticipantsNew to Johnson & JohnsonJohnson & Johnson · NCT00933283 · 18 enrolled
- Feb 14, 2013RECORDATI GROUP's first study: phase 3 study in Pain Related to CancerNew to RECORDATI GROUPRECORDATI GROUP · NCT01793480 · 146 enrolled · France
- Jan 20, 2022Lyndra's first study: phase 1 study in Opioid-Related DisordersNew to LyndraLyndra · NCT05251376
TargetBeta
“Mu opioid receptor agonist”ChEMBL 37, by rule
Other programs on OPRM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Oxycodonerule | Mundipharma | phase 4 | 72 |
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| axelopranrule | glycyx-therapeutics | phase 2 | 8 |
| Alfentanilrule | Sichuan Kelun Pharmaceutical | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05251376Opioid-Related Disorders | 1 | Withdrawn | Lyndra | Dec 19, 2022 | 0 |
| NCT01793480Pain Related to Cancer · France | 3 | Completed | RECORDATI GROUP | May 6, 2014 | 146 |
| NCT00933283Healthy Participants | 1 | Completed | Johnson & Johnson | Nov 2009 | 18 |
| NCT00279565Hepatitis C, Chronic | 4 | Terminated | Indivior Pharmaceuticals | Feb 2007 | 128 |
How it is read
Names in the registry
- “Methadone”, 12 entries
- “methadone”, 3 entries
- “fosamprenavir + ritonavir + methadone”, 1 entry
Conditions, from the studies’ own filings
- Infections, 2 studies
- Hepatitis C, 2 studies
- Pain, 1 study
- Opioid-Related Disorders, 1 study
- Hepatitis C, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.